dismiss

Clean Sweep Live Auction on Wed. February 27th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Ubicación actual:
>
> This Story


Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment
Advertisement

 

advertisement

 

Health IT Homepage

What will the right RIS system bring to your imaging department? There is no one-size-fits-all solution for RIS needs

Uber and Lyft showcase rideshare for healthcare at HIMSS19 Leading competitors seek to carve out patient transport verticals

Datatrak launches system for unifying imaging capture and adjudication workflows Enhances clinical trials, takes place on Datatrak's Enterprise Cloud platform

HIMSS Analytics releases new model to help adopt enterprise imaging Eight-stage DIAM model helps organizations track their progress

The exam room of the future: Nuance unveils AI-based clinical documentation product at HIMSS Improving patient experience and freeing up physicians

AI and personalized medicine to raise the bar in radiology reporting New innovations could provide myriad benefits to clinical workflow

Bitfury teams with MDW and Longenesis to create blockchain ecosystem for medical imaging Uphold, distribute and safeguard medical and diagnostic imaging

Hologic launches Unifi Analytics to curb mammo downtime Predicting tube failures before they happen and setting performance benchmarks

My observations from the HIMSS meeting The Jacobus Report

Imaging IT market insights The analysts at MD Buyline provide tips for navigating the market

Ibex's Second Read System

First AI pathology diagnostic system up and running in clinical setting

por John R. Fischer , Staff Reporter
The first AI-based pathology diagnostic system is up and running in a live clinical setting to assist in the confirmation of prostate cancer.

The Institute of Pathology at Maccabi Healthcare Services in Israel has deployed Ibex Medical Analytics’ Second Read (SR) System to identify various cell types and features within whole slide images of prostate core needle biopsies (PCNBs), including grading cancerous glands and other clinically significant features. Its use follows a pilot period in which it identified isolated major errors in retrospective PCNBs that were previously diagnosed as benign by pathologists.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



“Prostate cancer diagnosis is labor intensive,” Joseph Mossel, co-founder and CEO of Ibex, the strategic partner of Maccabi, told HCB News. “It requires reviewing a large number of biopsy slides with potential for a human pathologist to miss relatively small cancer foci. Furthermore, there is potential for more mundane human error such as missing a slide within a case, typing errors and so forth. These risks have become more pronounced in recent years with an ever-increasing workload and a global shortage of pathologists.”

The SR system analyzes the entire case and alerts users to discrepancies found with the original diagnosis.

Following its deployment, the solution utilized AI and machine learning techniques to identify a suspicious PCNB that was diagnosed earlier in the day as benign by a pathologist at the institute, which handles approximately 700 PCNBs out of 160,000 histology accessions annually.

Staff re-examined the PCNB and confirmed the presence of low-grade prostate cancer, demonstrating the higher efficiency and accuracy of the platform.

System training is derived from thousands of image samples of hundreds of PCNBs in multiple institutes. Digital images used for this initiative were produced by The Maccabi Pathology Institute’s Philips IntelliSite Pathology solution.

Training is currently limited to the prostate with the potential to teach the system how to diagnose other forms of cancer provided a large enough training set is available. This, however, could be a challenge for very rare types of cancer.

Mossel says, however, that the deployment of the system provides faster diagnoses and better management of population health in a cost-effective manner.

“The system allows for better management and improvement of population health while controlling for costs,” he said. “The deployment of AI-based tools for cancer diagnostics in pathology leads to faster diagnosis and associated treatment, increased efficiency, and increased accuracy.”

Ibex plans to expand the number of cancer types and clinical use cases the solution can address as part of its focus to make the SR system a commercially available product.

Availability of the platform is currently limited.

Health IT Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Directorio
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Trabajos/Entrenamiento
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Certificado recientemente
Ver usuarios certificados recientemente
Recientemente clasificado
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Mantenga el foro de los técnicos
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2019 DOTmed.com, Inc.
TODOS LOS DERECHOS RESERVADOS